The Drug Deal Disclosure Act requires the Department of Health and Human Services to publicly release all documents, communications, and agreements relating to drug pricing deals between federal agencies and pharmaceutical manufacturers entered into since January 20, 2025. The bill mandates disclosure within 30 days of enactment and covers agreements involving most-favored-nation pricing, direct-to-consumer sales, import exemptions, investment commitments, demonstration project exemptions, Strategic National Stockpile contributions, and FDA priority review vouchers. The bill permits withholding only of proprietary pricing information and information legally protected from disclosure, while prohibiting withholding based on reputational or political sensitivity. The bill also requires congressional reports and a joint CBO-GAO analysis of the economic and budgetary effects of disclosed agreements.
